<DOC>
	<DOCNO>NCT02534038</DOCNO>
	<brief_summary>Treatment disinhibition syndrome participant Neurodegenrative Disorder .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy AVP-786 Treatment Disinhibition</brief_title>
	<detailed_description>Eligible participant study must diagnosis Neurodegenerative Disorder must exhibit disinhibition syndrome sufficient severity warrant treatment . This multicenter , randomize , double-blind , placebo-controlled , cross-over study consist two 6-week treatment period . Approximately 12 participant enrol approximately 2 center United States . Following screening procedure assessment inclusion exclusion criterion , eligible participant randomize study .</detailed_description>
	<mesh_term>Dextromethorphan</mesh_term>
	<criteria>Documented diagnosis Neurodegenerative Disorder include frontotemporal dementia , Alzheimer 's disease ( AD ) , progressive supranuclear palsy ( PSP ) , corticobasal degeneration ( CBD ) , dementia Lewy body ( DBL ) , vascular cognitive disorder , Huntington 's disease , least 3 month prior Baseline The participant behavior 2 3 category disinhibited behavior definition behavioral variant frontotemporal dementia The behavioral change due preexist major psychiatric disorder ( e.g. , schizophrenia , bipolar disease , etc . ) due direct effect systemic illness , drug action , substance use Disinhibition scale score â‰¥4 3 core disinhibition item Frontal Behavioral Inventory ( FBI ) Screening Baseline Participants symptoms disinhibition secondary Neurodegenerative Disorders Participants myasthenia gravis Participants coexistent clinically significant unstable systemic disease could confound interpretation safety result study ( e.g. , malignancy [ except skin basalcell carcinoma untreated prostate cancer ] , poorly control diabetes , poorly control hypertension , unstable pulmonary , renal hepatic disease , unstable ischemic cardiac disease , dilate cardiomyopathy , unstable valvular heart disease )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Disinhibition</keyword>
</DOC>